Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154).

Although these findings did not reach statistical significance, the patients who developed strong T-cell immunity in terms of specific DTH and tetramer responses to PSA146-154 peptide within one year following vaccination demonstrated a trend towards greater OS ( Figure 4 ). 3.5.

also in 111,027 other papers